Brief: Mayne Pharma Posts FY A$47M Underlying EBITDA
29/01/2026 01:22
Jan 29 (Reuters) - Mayne Pharma Group Ltd MYX.AX: FY REPORTED REVENUE A$408.1 MILLION FY A$47M UNDERLYING EBITDA Further company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mayne Pharma
See all newsBrief: Mayne Pharma Group Says It Settles Us Patent Litigation Re Imvexxy With Teva USA
Deals of the day-Mergers and acquisitions
Brief: Mayne Pharma Says Supreme Court Dismisses Cosette Appeal
Deals of the day-Mergers and acquisitions
Australian court dismisses Cosette appeal to drop Mayne Pharma takeover (updated)